MAFA is a member of the MAF family of basic leucine zipper transcription factors and is a critical regulator of insulin gene expression and islet b-cell function. To be degraded by the proteasome, MAFA must be phosphorylated by GSK3 and MAP kinases at multiple serine and threonine residues (Ser49, Thr53, Thr57, Ser61, and Ser65) within its amino-terminal domain. In this study, we report that MAFA degradation is stimulated by PA28g (REGg and PSME3), a member of a family of proteasome activators that bind and activate the 20S proteasome. To date, only a few PA28g-proteasome pathway substrates have been identified, including steroid receptor coactivator 3 (SRC3) and the cell cycle inhibitor p21 (CIP1). PA28g binds to MAFA, induces its proteasomal degradation, and thereby attenuates MAFA-driven transcriptional activation of the insulin promoter. Co-expression of GSK3 enhanced the PA28g-mediated degradation of MAFA, but mutants that contained alanine substitutions at the MAFA phosphorylation sites did not bind PA28g and were resistant to degradation. We also found that a PA28g mutant (N151Y) that did not stimulate p21 degradation enhanced MAFA degradation, and another mutant (K188D) that promoted greater p21 degradation did not enhance MAFA degradation. These results suggest that PA28g stimulates MAFA degradation through a novel molecular mechanism that is distinct from that for the degradation of p21.
Introduction
MAFA is a member of the MAF family of basic leucine zipper transcription factors. In avians, MAFA/L-MAF has been identified as a neuroretina-specific transcript (Benkhelifa et al. 1998) or a transcription factor that binds to the lens-specific enhancer in crystallin genes (Ogino & Yasuda 1998) . Gain-and loss-of-function experiments in the developing chicken embryo revealed that MAFA/L-MAF is a key regulator of lens development (Reza et al. 2002) .
In mammals, MAFA has been identified as a transactivator of the insulin gene that binds to a critical cis-regulatory element within the promoter termed C1/RIPE3b (Kataoka et al. 2002 , Olbrot et al. 2002 , Kajihara et al. 2003 , Matsuoka et al. 2003 . MAFA is exclusively expressed in b-cells in the pancreas (Kataoka et al. 2004 , Zhang et al. 2005 , Nishimura et al. 2006 and plays a critical role in establishing b-cell-specific expression of the insulin gene together with the other b-cell-enriched transcription factors, PDX1 and BETA2/NEUROD (Aramata et al. 2005 , Docherty et al. 2005 , Kaneto et al. 2005 . MAFA also regulates a set of b-cell-specific genes, including glucose transporter 2 (glut2) and granuphilin (Zhang et al. 2005 , Kato et al. 2006 , Wang et al. 2007 . In Mafa knockout mice, islets are normal at birth, but b-cells exhibit a deficiency in glucose-stimulated insulin secretion over time and show progressive degeneration by 8-12 weeks of age (Zhang et al. 2005 , Artner et al. 2007 , Nishimura et al. 2008 ). These observations indicate that MAFA regulates the maturation, functional maintenance, and survival of b-cells. Recently, it was also shown that MAFA regulates intra-thymic expression of insulin and affects susceptibility to type I diabetes (Noso et al. 2010) .
Previous studies have demonstrated that phosphorylation plays critical roles in the regulation of MAFA activity. The amino-terminal domain of MAFA is first phosphorylated by an unidentified priming kinase at Ser65 and then sequentially by GSK3 at Ser61, Thr57, Thr53, and Ser49 (Han et al. 2007 , Rocques et al. 2007 ). Thr57 and Ser65 can also be phosphorylated by ERK and/or p38 MAP kinase (Benkhelifa et al. 2001 , Ochi et al. 2003 , Sii-Felice et al. 2005 . Phosphorylation at these sites is required for proteasomal degradation of MAFA protein (Ochi et al. 2003 , Han et al. 2007 , Rocques et al. 2007 , and mutations at these phosphorylation sites influence the transforming and differentiation-inducing activities of MAFA (Benkhelifa et al. 2001 , Nishizawa et al. 2003 , Ochi et al. 2003 , Pouponnot et al. 2006 , Rocques et al. 2007 ). However, the molecular mechanism by which phosphorylated MAFA is degraded is unknown.
PA28g (REGg and PSME3) is a member of a family of proteasome activators that bind the 20S subunit of the proteasome (Dubiel et al. 1992 , Ma et al. 1992 . PA28g is predominantly localized within the nucleus and forms homoheptamers, whereas PA28a and PA28b, other members of this family, form heteroheptamers in the cytoplasm (Realini et al. 1997 , Wojcik et al. 1998 . Biochemical and crystal structural analyses of PA28 family members have suggested that PA28 heptamers associate with both ends of the 20S proteasome like 'caps' through interactions between the proteasome and the carboxy-terminal tail of each monomer. On these interactions, the 'activation loop' of PA28 induces a conformational change of the 20S proteasome subunit and stimulates the protease activity (Whitby et al. 2000 , Forster et al. 2005 . Experiments using peptide substrates revealed that PA28a and PA28b stimulate three types of 20S proteasome catalytic activities: trypsin-like, chymotrypsin-like, and post-glutamyl peptidyl hydrolyzing activities. In contrast, PA28g stimulates only trypsin-like activity (Realini et al. 1997) .
To date, only a few protein substrates of the PA28g-proteasome pathway have been identified. These substrates include steroid receptor coactivator 3 (SRC3), hepatitis C virus core protein, the tumor suppressor p53, and the cell cycle inhibitors p21 (CIP1/WAF1), p16 (INK4A), and p19 (ARF) (Moriishi et al. 2003 , Li et al. 2006 , Chen et al. 2007 , Zhang & Zhang 2008 . PA28g directly binds to SRC3 and p21 and promotes their proteasomal degradation independent of poly-ubiquitination and the 19S subunit. In contrast, PA28g stimulates the degradation of p53 by enhancing its ubiquitination by MDM2. These observations suggest that PA28g is a multi-functional protein involved in the degradation of a subset of nuclear proteins.
In this study, we demonstrate that degradation of MAFA is stimulated by PA28g. PA28g bound to MAFA and induced its proteasomal degradation in a phosphorylation-dependent manner. In addition, PA28g attenuated MAFA-driven transcriptional activation of the insulin promoter. Using well-characterized PA28g mutants (N151Y and K188D) (Zhang et al. 1998 , Li et al. 2001 , we found that PA28g stimulated degradation of MAFA and p21 through distinct molecular mechanisms.
Materials and methods

Plasmids
The mammalian expression vector for hemagglutinin (HA)-tagged mouse Mafa (pHygEF2/HA-m-MafA) and its derivatives (IRES-EGFP fusions and amino acid substitution mutants) were described previously (Han et al. 2007) .
To construct the expression vectors for the PA28a, PA28b, and PA28g FLAG epitope fusion proteins (pHygEF2/FLAG-PA28a, FLAG-PA28b, and FLAGPA28g), cDNA fragments containing the entire open frame of mouse PA28a, PA28b, and PA28g were amplified from total RNA isolated from MIN6 mouse insulinoma cells by reverse transcriptase (RT)-PCR using the following primers: Pa28a, 5 0 -AGAACTAG-TATGGCCACACTGAGGGTCCATCCC-3 0 and 5 0 -AG-AGCGGCCGCTCAATAGATCATTCCCTTGGTTT-3 0 ; Pa28b, 5 0 -AGAACTAGTATGGCCAAGCCTTGTGGGG-TCCG-3 0 and 5 0 -AGAGCGGCCGCTCAGTACATCGA-TGGCTTTTCTT-3 0 ; and Pa28g, 5 0 -AGAACTAGTA-TGGCCTCGTTGCTGAAGGTGG-3 0 and 5 0 -AGAGCGG-CCGCTAGTACAGTGTCTCTGCATTG-3 0 . The amplified fragments were cloned into the pHygEF2/FLAG-SUMO-2 plasmid (Kanai et al. 2010) by replacing the SpeI-NotI fragment.
To construct the FLAG-tagged GSK3b expression vector (pHygEF2/FLAG-GSK3b), the mouse GSK3b open reading frame was amplified by RT-PCR from mouse liver total RNA using the following primers: 5 0 -ACTAGTACCATGGATTACAAGGATGACGACGATA-AGGGAGGCCTCATGTCGGGGCGACCGAGAACC-3 0 and 5 0 -GGCACTCAAGTAAGTGCTGG-3 0 . The amplified fragment was inserted into the pCRII-TOPO plasmid (Invitrogen) by TA cloning. The SpeI-NotI fragment was excised from the resulting plasmid and inserted into the pHygEF2 vector following digestion with XbaI and NotI.
All of the PA28g (N151Y and K188D) and GSK3b (S9A and K85R) point mutants were generated by site-directed overhang extension PCR mutagenesis (Ho et al. 1989) .
Transfection, immunoprecipitation, and immunoblotting
NIH3T3 or 293T cells grown in 24-well plates were transfected with a total of 0 . 8 mg plasmid using 2 ml lipofectamine 2000 reagent (Invitrogen). In1024 cells were transfected with a total of 1 . 6 mg plasmid using 4 ml lipofectamine 2000 (Invitrogen). After 24 h of transfection, whole cell extracts were prepared by the direct addition of 4! SDS sample buffer (200 mM Tris-HCl (pH 6 . 8), 8% SDS, 400 mM dithiothreitol, 0 . 2% bromophenol blue, and 40% glycerol) and then subjected to immunoblot analysis as described previously (Kataoka et al. 2002) .
For immunoprecipitation, HeLa cells grown in 6-well plates were transfected with a total of 3 . 2 mg plasmid using 8 ml lipofectamine 2000 (Invitrogen). Whole cell extracts were prepared by cell lysis in 800 ml NETN buffer (150 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH 7 . 5, and 0 . 1% NP-40) containing a protease inhibitor cocktail (Nacarai tesque, Kyoto, Japan), sonicated for 20 s, and then centrifuged. Aliquots of the extracts were subjected to immunoprecipitation using anti-HA-agarose (Roche) and then examined by immunoblot analysis. The antibodies used were as follows: anti-HA (MBL, Nagoya, Japan), anti-FLAG (M2, Sigma), anti-GFP (Clontech, Mountain View, CA, USA), anti-TF-IID (TATA-binding protein (TBP) SI-1; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-c-Maf (M-153, Santa Cruz), and anti-PA28g (PW8190; Enzo Life Sciences, Plymouth Meeting, PA, USA). MG132, epoxomicin, lactacystin (Merck), SB216763 (Tocris Bioscience, Ellsville, MO, USA), and cycloheximide (CHX, Sigma) were obtained commercially.
RNAi
NIT-1 cells grown in 24-well plates were transfected with 15 pmol siRNA using PrimaPort (Credia Japan, Kyoto, Japan) and were subjected to a second round of transfection 24 h later. A synthetic siRNA targeting mouse Pa28g was purchased from Invitrogen (Psme3-MSS208070).
The pEF3-GFPBsr-U6 plasmid to express short-hairpin RNA (shRNA) was designed to clone a double synthetic oligonucleotide into the U6 small nuclear RNA promoter using BseRI-BglII restriction sites. The oligonucleotides used for silencing human PA28g were as follows: 5 0 -GAACCAAGGTGTTTGTGAttcaagagaTCACAAACACCTTGGTTCCttttt-3 0 and 5 0 -GATCaaaaaGGAACCAAGGTGTTTGTGAtctcttgaaTCACAAACACCTTGGTTCca-3 0 .
Luciferase assay
The luciferase reporter plasmid (pGL4/h-ins-p) was constructed by inserting a KpnI-HindIII fragment of the pGL2-based h-ins-p-luc plasmid (Kataoka et al. 2002) into pGL4.10 (Promega). pEF-Rluc were described previously (Kataoka et al. 2001) . NIH3T3 cells grown in 24-well plates were transfected with a total of 0 . 8 mg plasmid DNA (0 . 05 mg pGL4/h-ins-p, 0 . 05 mg pEF-Rluc, and 0 . 7 mg of the expression plasmids) using lipofectamine 2000 (Invitrogen). Cells were harvested 24 h after transfection, and the firefly and Renilla luciferase activities were measured using the Dual Luciferase Pa28g Assay System (Promega). Data represent the average GS.E.M. of two independent experiments. Statistical significance was calculated using ANOVA (P!0 . 05).
Results
PA28g reduces the amount of MAFA protein
To test the possible involvement of PA28g in the regulation of the amounts of MAFA protein, an expression plasmid for HA-tagged full-length MAFA (HA-MAFA) fused to IRES-EGFP under the control of the constitutively active EF1a promoter was used (Fig. 1A) . We transfected NIH3T3 cells with a constant amount of this plasmid together with an increasing amount of an expression plasmid for FLAG-tagged PA28g (F-PA28g). NIH3T3 was used as a recipient cell for this assay because HA-MAFA protein is relatively stable in this cell line (Han et al. 2007 , see also Fig. 3C ).
Cell extracts were prepared, and the expression levels of the transgenes were analyzed by immunoblotting with anti-HA and anti-FLAG antibodies. Expression of EGFP was also analyzed to normalize the transfection efficiency, and TBP was monitored as a loading control. The amount of HA-MAFA was reduced by F-PA28g co-expression in a dose-dependent manner (Fig. 1B) .
To examine the role of endogenous PA28g in the regulation of MAFA protein levels, we used 293T cells because HA-MAFA protein is relatively unstable in this cell line (see Fig. 3D ). 293T cells were transfected with an expression plasmid for HA-MAFA together with the shRNA expression vector designed to target PA28g. Immunoblot analysis showed that the amount of MAFA was increased by the knockdown of PA28g (Fig. 1C) .
The effect of PA28g knockdown on the amount of endogenous MAFA protein was examined. An siRNA designed to target PA28g was transfected into a b-cellderived cell line NIT-1 in which endogenous MAFA protein was expressed. Immunoblot analysis showed that endogenous PA28g was reduced in cells transfected with Pa28g-siRNA and that endogenous MAFA protein was increased in these cells (Fig. 1D) . These results indicated that PA28g might negatively regulate the amount of MAFA protein by inducing degradation.
Then, the effect of PA28a and PA28b, other PA28 family members, on MAFA reduction was determined. PA28g predominantly localizes in the nuclei and forms a homoheptamer, whereas PA28a and PA28b localize in the cytoplasm and form heteromeric hexamers (Realini et al. 1997 , Wojcik et al. 1998 . As shown in Fig. 1E , PA28a or PA28b alone or in combination did not significantly influence the amount of HA-MAFA.
Phosphorylation of MAFA is required for PA28g-mediated reduction
Previous studies have shown that MAFA degradation is dependent on phosphorylation at multiple serine and threonine residues (Ser49, Thr53, Thr57, Ser61, and Ser65) in the amino-terminal domain (Han et al. 2007 , Rocques et al. 2007 . To investigate the role of these phosphorylation sites in MAFA downregulation by PA28g, a MAFA substitution mutant (5A) in which these serine and threonine residues were replaced by alanine residues was examined ( Fig. 2A) . As we previously observed (Han et al. 2007) , the electrophoretic mobility of the 5A mutant protein was higher than that of wild-type (WT) MAFA due to the absence of phosphorylation at the mutated sites (Fig. 2B) . In contrast to WT MAFA, the 5A mutant was resistant to PA28g-induced reduction. These results suggested that phosphorylation at these amino acid residues is required for the PA28g-mediated reduction of the amount of MAFA.
To determine whether PA28g affects the transcriptional activity of MAFA, a luciferase reporter gene driven A luciferase reporter plasmid driven by the human insulin promoter (pGL4/h-ins-p) and the indicated combinations of expression plasmids for F-PA28g (0 . 5 mg) and HA-MAFA (WT or 5A) (0 . 2 mg) were co-transfected into NIH3T3 cells. The luciferase activity was measured and was expressed as fold increase over the luciferase activity in cells that received an empty expression plasmid. Statistical significance was calculated using ANOVA (*P!0 . 05). NS, not significant.
K KANAI and others . PA28g-dependent degradation of MAFA by the human insulin promoter was co-transfected into NIH3T3 cells together with expression plasmids for HA-MAFA and F-PA28g alone or in combination (Fig. 2C) . As previously demonstrated, both WT MAFA and the 5A mutant stimulated reporter activity to a similar degree (Han et al. 2007 ). Co-expression of F-PA28g reduced transcriptional activation by WT MAFA, but not by the 5A mutant. These results suggested that PA28g suppressed the transcriptional activity of MAFA by reducing the amount of protein.
PA28g enhances proteasomal degradation of MAFA
To determine whether PA28g reduces the amount of MAFA by enhancing its degradation, NIH3T3 cells were treated with the proteasome inhibitors MG132, epoxomicin, or lactacystin. These drugs blocked the effect of PA28g on MAFA (Fig. 3A) . In 293T cells, MG132 treatment increased the amount of MAFA protein (Fig. 3B) . Knockdown of PA28g resulted in an accumulation of MAFA, and MG132 did not induce further increase in MAFA in these cells. These results indicated that PA28g promoted the degradation of MAFA by way of the proteasome. The degradation rates of MAFA in the absence or presence of F-PA28g were measured. Nascent protein synthesis was blocked in transfected cells using CHX treatment and the amount of HA-MAFA was measured by immunoblotting. WT HA-MAFA disappeared more rapidly in the presence of F-PA28g than in its absence (Fig. 3C) . The phosphorylation-deficient MAFA mutant (5A) was stable, and its degradation rate was The reduction of endogenous PA28g by shRNA resulted in a significant increase in the half-life of WT HA-MAFA protein (Fig. 3D) . These results demonstrated that PA28g promoted proteasomal degradation of MAFA that depended on its phosphorylation status.
PA28g associates with MAFA depending on phosphorylation
The interaction between MAFA and PA28g was examined by the co-expression of WT or 5A HA-MAFA and F-PA28g in HeLa cells. Cell extracts were subjected to immunoprecipitation with an anti-HA antibody and immunoblot analysis with anti-HA and anti-FLAG antibodies (Fig. 4) . In the context of WT HA-MAFA co-expression, F-PA28g was detected in the anti-HA immunoprecipitate. However, the MAFA 5A mutant did not co-immunoprecipitate F-PA28g. Thus, MAFA interacted with PA28g in a phosphorylation-dependent manner.
GSK3b cooperates with PA28g to induce MAFA degradation
We previously demonstrated that MAFA is first phosphorylated at Ser65 by an unidentified kinase and is then sequentially phosphorylated at Ser61, Thr57, Thr53, and Ser49 by GSK3 (Han et al. 2007) . We thus investigated the role of GSK3 in PA28g-mediated degradation of MAFA. Treatment of the transfected cells with SB216763, a specific inhibitor of GSK3, induced the accumulation of hypo-phosphorylated forms of HA-MAFA and blunted the PA28g-mediated degradation of MAFA (Fig. 5A ). This result indicated that the phosphorylation of MAFA by GSK3 is required for PA28g-mediated protein degradation. Then, NIH3T3 cells were transfected with a constant amount of the HA-MAFA expression plasmid and an increasing amount of the F-PA28g expression vector. Expression plasmids for WT, constitutively active (CA), or kinase-deficient (KD) forms of GSK3b were also included. Cell extracts were analyzed for protein expression by immunoblotting (Fig. 5B) . In this experimental setting, the amount of the PA28g expression vector was kept low so that PA28g alone promote only marginal degradation of WT MAFA. However, co-expression of GSK3b, particularly the CA form, enhanced MAFA degradation by PA28g. In contrast, the KD form of GSK3b had little effect, indicating that the stimulation of PA28g-mediated MAFA degradation by GSK3b depends on its kinase activity. The amount of the 5A form of MAFA was not largely affected by co-expression of F-PA28g or either form of GSK3b. Interaction between HA-MAFA and F-PA28g was analyzed using an immunoprecipitation assay. HeLa cells were transfected with an expression plasmid for F-PA28g together with an empty vector or an expression plasmid for HA-MAFA (WT or 5A). To avoid MAFA degradation, cells were treated with the proteasome inhibitors MG132 (5 mM) for 8 h before harvest. Cell extracts were subjected to immunoprecipitation with an anti-HA antibody, and the immune complexes (a-HA I.P., right panels) were examined by immunoblot analysis using an anti-HA or anti-FLAG antibody. As a control, the total cell extract (input, left panels) was also analyzed.
These results indicate that GSK3b cooperates with PA28g to induce the degradation of MAFA through the phosphorylation of its target serine and threonine residues.
PA28g-mediated degradation of MAFA and p21 occurs through distinct molecular mechanisms
To investigate the molecular mechanism by which PA28g stimulates MAFA protein degradation, we utilized two well-defined PA28g mutants. It has been proposed that the PA28g heptamer binds to the 20S proteasome and stimulates its trypsin-like activity (Realini et al. 1997) . The N151Y mutant is capable of binding to the 20S proteasome but is unable to enhance its catalytic activity (Zhang et al. 1998) . In contrast, the K188D mutant is hyperactive, activating not only the 20S proteasome trypsin-like activity but also its chymotrypsin-like and post-glutamyl peptidyl hydrolyzing activities (Li et al. 2001) .
To confirm the characteristics of these mutants, we tested their ability to stimulate degradation of the p21/CIP1, a previously identified PA28g target (Chen et al. 2007 , Li et al. 2007 . As expected, p21 degradation was enhanced by WT PA28g but not by the N151Y mutant (Fig. 6A) , whereas the K188D mutant more potently induced p21 degradation. We then tested the effect of these mutants on MAFA stability (Fig. 6B) . The defective N151Y and the WT PA28g induced MAFA degradation to a similar extent, whereas the hyperactive mutant K188D did not induce MAFA degradation. These results indicated that PA28g stimulates the degradation of p21 and MAFA by distinct molecular mechanisms.
Discussion
Previous studies have shown that the phosphorylation of MAFA at multiple sites (Ser49, Thr53, Thr57, Ser61, and Ser65) by a priming kinase and GSK3 are critical for its proteasomal degradation (Han et al. 2007 , Rocques et al. 2007 ), but the molecular mechanism underlying this degradation was unknown. In this study, several lines of evidence suggest that PA28g is involved in the degradation of MAFA. Overexpression of PA28g stimulated the degradation of MAFA depending on the phosphorylation and attenuated transactivation of the insulin promoter. Furthermore, GSK3 cooperated with PA28g to enhance MAFA degradation. Conversely, the knockdown of PA28g using siRNA or shRNA increased endogenous and exogenous MAFA protein, while pharmacological inhibition of GSK3 eliminated the PA28g-mediated degradation of MAFA. Co-transfection and co-immunoprecipitation experiments revealed that PA28g binding to MAFA was dependent on phosphorylation.
Previous reports have demonstrated that PA28g directly binds to p21 and SRC3 and stimulates their degradation via the 20S proteasome by an unknown mechanism that is not dependent on poly-ubiquitination and the 19S regulatory subunit (Chen et al. 2007 , Li et al. 2007 ). Using two well-characterized PA28g mutants, N151Y and K188D, we showed that PA28g stimulates the degradation of MAFA and p21 by distinct molecular mechanisms. The N151Y mutant can bind to the 20S proteasome but is unable to enhance its protease activity. Here, the N151Y mutant did not stimulate p21 degradation but it enhanced MAFA degradation. In contrast, the 'hyperactive' K188D mutant stimulated p21 degradation more than WT PA28g but it did not enhance MAFA degradation. Additional studies are required to elucidate the exact molecular mechanism to explain how PA28g enhances MAFA degradation.
PA28g knockout mice exhibit growth retardation, and embryonic fibroblasts derived from them have defects in mitosis and apoptosis (Murata et al. 1999) . Thus, it has been proposed that p21 and p53 are potential targets of PA28g in the regulation of cell cycle progression and apoptosis (Chen et al. 2007 , Li et al. 2007 , Zhang & Zhang 2008 , but the exact role of PA28g in the cell cycle and other biological processes is largely unknown. In this study, MAFA was identified as a new target of PA28g. Examination of the development and function of pancreatic b-cells in PA28g-knockout mice is warranted to determine whether PA28g is involved in b-cell morphology and function. As MAFA regulates cell differentiation as well as oncogenic transformation (Nishizawa et al. 2003 , Pouponnot et al. 2006 , PA28g may also be involved in these processes. Further studies of PA28g and its target proteins will help define its role in the degradation of a subset of nuclear proteins important in a variety of biological processes.
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